S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
The 3-Stock Retirement Blueprint (Ad)
This Is Why Daktronics Fell 40% In One Day 
Why You Should Avoid Carvana Even if it Avoids Bankruptcy
Why Your IRA Could Crash on January 16th? (Ad)
On the money: Yellen's next milestone is name on US currency
Biden releasing nearly $36B to aid pensions of union workers
Why Your IRA Could Crash on January 16th? (Ad)
Are Investors Hearing The End Of Spotify's Downtrend?
Is It Time To Throw In The Towel On Gamestop?
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
The 3-Stock Retirement Blueprint (Ad)
This Is Why Daktronics Fell 40% In One Day 
Why You Should Avoid Carvana Even if it Avoids Bankruptcy
Why Your IRA Could Crash on January 16th? (Ad)
On the money: Yellen's next milestone is name on US currency
Biden releasing nearly $36B to aid pensions of union workers
Why Your IRA Could Crash on January 16th? (Ad)
Are Investors Hearing The End Of Spotify's Downtrend?
Is It Time To Throw In The Towel On Gamestop?
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
The 3-Stock Retirement Blueprint (Ad)
This Is Why Daktronics Fell 40% In One Day 
Why You Should Avoid Carvana Even if it Avoids Bankruptcy
Why Your IRA Could Crash on January 16th? (Ad)
On the money: Yellen's next milestone is name on US currency
Biden releasing nearly $36B to aid pensions of union workers
Why Your IRA Could Crash on January 16th? (Ad)
Are Investors Hearing The End Of Spotify's Downtrend?
Is It Time To Throw In The Towel On Gamestop?
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
The 3-Stock Retirement Blueprint (Ad)
This Is Why Daktronics Fell 40% In One Day 
Why You Should Avoid Carvana Even if it Avoids Bankruptcy
Why Your IRA Could Crash on January 16th? (Ad)
On the money: Yellen's next milestone is name on US currency
Biden releasing nearly $36B to aid pensions of union workers
Why Your IRA Could Crash on January 16th? (Ad)
Are Investors Hearing The End Of Spotify's Downtrend?
Is It Time To Throw In The Towel On Gamestop?
NASDAQ:COLL

Collegium Pharmaceutical - COLL Price Target & Analyst Ratings

$22.50
+0.63 (+2.88%)
(As of 12/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$21.78
$22.79
50-Day Range
$16.02
$23.02
52-Week Range
$14.04
$23.27
Volume
139,794 shs
Average Volume
302,452 shs
Market Capitalization
$755.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.75

Collegium Pharmaceutical Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 4 Analyst Ratings

Consensus Analyst Price Target

$32.75
45.56% Upside
High Prediction$42.00
Average Prediction$32.75
Low Prediction$26.00
TypeCurrent
12/9/21 to 12/9/22
1 Month Ago
11/9/21 to 11/9/22
3 Months Ago
9/10/21 to 9/10/22
1 Year Ago
12/9/20 to 12/9/21
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
2 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$32.75$32.75$33.25$25.33
Predicted Upside45.56% Upside64.62% Upside62.35% Upside19.57% Upside
Get Collegium Pharmaceutical Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter.


COLL Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

COLL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Collegium Pharmaceutical Stock vs. The Competition

TypeCollegium PharmaceuticalMedical CompaniesS&P 500
Consensus Rating Score
2.75
2.66
2.48
Consensus RatingModerate BuyBuyHold
Predicted Upside45.56% Upside682.68% Upside14.88% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
347
64.38%
Underperform Votes
192
35.62%
Avg. Outperform Votes
163
66.26%
Avg. Underperform Votes
83
33.74%
Avg. Outperform Votes
853
68.13%
Avg. Underperform Votes
399
31.87%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/4/2022Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$36.00 ➝ $34.00+88.57%
8/15/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
O. Livnat
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeNeutral
2/22/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$36.00 ➝ $42.00+93.10%
2/15/2022Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
B. Folkes
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$18.00 ➝ $26.00+30.65%
7/14/2020BWS Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
H. Khorsand
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSell$8.00-50.19%
5/26/2020Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral
2/28/2020William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Tim Lugo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
2/19/2020Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$43.00+86.07%
(Data available from 12/9/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












COLL Price Target - Frequently Asked Questions

What is Collegium Pharmaceutical's consensus rating and price target?

According to the issued ratings of 4 analysts in the last year, the consensus rating for Collegium Pharmaceutical stock is Moderate Buy based on the current 1 hold rating and 3 buy ratings for COLL. The average twelve-month price prediction for Collegium Pharmaceutical is $32.75 with a high price target of $42.00 and a low price target of $26.00. Learn more on COLL's analyst rating history.

Do Wall Street analysts like Collegium Pharmaceutical more than its competitors?

Analysts like Collegium Pharmaceutical more than other Medical companies. The consensus rating for Collegium Pharmaceutical is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how COLL compares to other companies.

Do MarketBeat users like Collegium Pharmaceutical more than its competitors?

MarketBeat users like Collegium Pharmaceutical less than other Medical companies. 64.38% of MarketBeat users gave Collegium Pharmaceutical an outperform vote while medical companies recieve an average of 66.26% outperform votes by MarketBeat users.

Does Collegium Pharmaceutical's stock price have much upside?

According to analysts, Collegium Pharmaceutical's stock has a predicted upside of 64.62% based on their 12-month price targets.

What analysts cover Collegium Pharmaceutical?

Collegium Pharmaceutical has been rated by Needham & Company LLC in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:COLL) was last updated on 12/9/2022 by MarketBeat.com Staff